Sage Therapeutics and Biogen reported topline results from the Phase 2 KINETIC Study evaluating SAGE-324 in the treatment of patients with essential tremor (ET). The…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.